Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-04-30

Study Completion Date

2004-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up

NCT01973946

Cancer

COMPLETED NA

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725

Cancer

COMPLETED NA

Automated Telephone Monitoring for Symptom Management

NCT00799084

Carcinoma

COMPLETED PHASE2

A Computer-Based System for Symptom Reporting in Patients With Cancer Undergoing Treatment

NCT03979846

Caregiver Malignant Neoplasm

COMPLETED NA

Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic

NCT04464486

Oncology

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers. The symptoms monitored in the project were nausea/vomiting, pain, sore mouth, diarrhea, constipation, depressed mood, anxiety, trouble sleeping, and fatigue. The study randomly assigned participants into either the intervention group or the group that received usual care from their oncology providers without alert notifications. All participants called the automated system daily to report their symptom presence, severity, and distress. When participants in the intervention group rated symptoms at moderate (4-7) to severe (8-10) levels an e-mail alert report of their symptom information was sent to the participant's medical oncologist and oncology nurse. The usual care group also reported symptoms daily to the automated system but their information was not sent to the providers. Participants in the usual care group were told daily to call their oncology provider if they had concerns about their symptoms. The two study groups were compared over chemotherapy cycles 2 and 3 on symptom presence, severity, and distress. Functional status, patient reported degree of symptom interference with normal activities, and work attendance if they had indicated that they worked during their treatment were also recorded. In addition, the groups were compared for the number and purpose of unscheduled patient-provider contacts, visits to the emergency department or urgent care facility, and unscheduled hospitalizations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Provider Unrelieved Symptom Alert

Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.

Group Type EXPERIMENTAL

Provider Unrelieved Symptom Alert

Intervention Type OTHER

The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.

Attentional Control Usual Care Group

Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Provider Unrelieved Symptom Alert

The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (18 or older)
* Histological Diagnosis of Cancer
* Life Expectancy of at least 6 months
* Cognitively able to participate (verified by provider team)
* Initiated a course of new Chemotherapy that is planned for a minimum of 3 cycles
* Had Poorly controlled symptoms during the first cycle of chemotherapy
* Care under the direction of one of the designated provider teams
* English or Spanish speaking
* Has access to a telephone on a daily basis
* Able to use the telephone unassisted

Exclusion Criteria

* Receiving concurrent radiation therapy because they would be in daily contact with oncology care providers.
* Patients seeing the provider team for recommendation of chemotherapy regimen but other providers then administer treatment at different site
* Patients receiving a treatment regimen with only biotherapy agents or agents not associated with the symptoms monitored

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No